Roche is ‘on par’ with Novo, Lilly in GLP-1 race after $2.7B Carmot deal

By picking up Carmot and its three lead molecules — which are all GLP-1 analogues and being tested in advanced stages of clinical trials — Roche is on par with Novo Nordisk and Eli Lilly, the current leaders in the obesity drug space, according to analytics company GlobalData.